Program
tegoprazan
Also written as “Tegoprazan”, “Tegoprazan 50 mg” and “BLI5100”.
Its studies are mostly in Esophagitis · Non-Erosive Reflux Disease · Gastroesophageal Reflux · Peptic Ulcer · Duodenal Ulcer, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HK inno.N | 376 open or running | phase 4since Mar 13, 2020 | Nov 14, 2011 | Jan 31, 2027phase 1 · NCT07853248 |
| Shandong Luoxin Pharmaceutical Group Stock | 70 open or running | phase 3since Jul 9, 2018 | Jan 25, 2018 | none ahead |
| Sebela Pharmaceuticals | 30 open or running | phase 3since Oct 17, 2022 | Oct 17, 2022 | none ahead |
| Carnot Laboratories | 11 open or running | phase 4since May 20, 2025 | May 20, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 33 studies since Nov 14, 2011.
- Apr 25, 2022Phase 1 study in HealthyHK inno.N · NCT05353010 · 12 enrolled · Korea, Republic of
- Oct 9, 2022Phase 3 study in Helicobacter Pylori InfectionShandong Luoxin Pharmaceutical Group Stock · NCT05577468 · 561 enrolled · China
- Oct 17, 2022Sebela Pharmaceuticals's first studies: 2 phase 3 studiesNew to Sebela PharmaceuticalsSebela Pharmaceuticals · NCT05587322, NCT05587309
- Jan 18, 2023Phase 4 study in Gastroesophageal RefluxHK inno.N · NCT05701540 · 338 planned · Korea, Republic of
- Feb 2, 2023Phase 1 study in HealthyHK inno.N · NCT05723510 · 87 enrolled · Korea, Republic of
- May 5, 2023Phase 3 study in Non-Erosive Reflux DiseaseSebela Pharmaceuticals · NCT05890001 · 400 enrolled · United States
- May 10, 2023Phase 1 study in Healthy SubjectsShandong Luoxin Pharmaceutical Group Stock · NCT05883306 · 6 enrolled · China
- May 23, 2023Phase 2 study in Helicobacter Pylori InfectionHK inno.N · NCT05933031 · 381 planned · Korea, Republic of
- Jun 2, 2023Phase 1 study in HealthyShandong Luoxin Pharmaceutical Group Stock · NCT05915871 · 22 enrolled · China
- Dec 1, 2023Phase 1 study in HealthyHK inno.N · NCT06164834 · 48 planned · Korea, Republic of
- Feb 20, 2024Phase 1 study in HealthyHK inno.N · NCT06332638 · 36 planned · Korea, Republic of
- May 20, 2025Carnot Laboratories's first study: phase 4 study in Gastroesophageal RefluxNew to Carnot LaboratoriesCarnot Laboratories · NCT06991348 · 128 planned · Mexico
- Sep 13, 2026Phase 4 study in Gastroesophageal RefluxHK inno.N · NCT07826455 · 100 planned
- Sep 14, 2026Phase 1 study in Healthy Adult MaleHK inno.N · NCT07853248 · 34 planned · South Korea
Ahead
- Jan 31, 2027Primary completion: phase 1 study in Healthy Adult MaleHK inno.N · NCT07853248
- Jul 31, 2028Primary completion: phase 4 study in Gastroesophageal RefluxHK inno.N · NCT07826455
TargetBeta
“Potassium-transporting ATPase blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07853248Healthy Adult Male · South Korea | 1 | Not yet recruiting | HK inno.N | Jan 31, 2027 | 34 |
| NCT07826455Gastroesophageal Reflux | 4 | Not yet recruiting | HK inno.N | Jul 31, 2028 | 100 |
| NCT06991348Gastroesophageal Reflux · Mexico | 4 | Recruiting | Carnot Laboratories | Nov 30, 2025 | 128 |
| NCT06332638Healthy · Korea, Republic of | 1 | By invitation | HK inno.N | Jul 31, 2024 | 36 |
| NCT06164834Healthy · Korea, Republic of | 1 | Not yet recruiting | HK inno.N | Nov 2024 | 48 |
| NCT05915871Healthy · China | 1 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Apr 28, 2023 | 22 |
| NCT05933031Helicobacter Pylori Infection · Korea, Republic of | 2 | Recruiting | HK inno.N | Dec 31, 2024 | 381 |
| NCT05883306Healthy Subjects · China | 1 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Jul 21, 2022 | 6 |
| NCT05890001Non-Erosive Reflux Disease · United States | 3 | Completed | Sebela Pharmaceuticals | Oct 8, 2024 | 400 |
| NCT05723510Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 17, 2023 | 87 |
| NCT05701540Gastroesophageal Reflux · Korea, Republic of | 4 | Recruiting | HK inno.N | Dec 31, 2024 | 338 |
| NCT05587322Non-Erosive Reflux Disease · United States | 3 | Completed | Sebela Pharmaceuticals | Oct 13, 2023 | 788 |
| NCT05587309Erosive Esophagitis · United States | 3 | Completed | Sebela Pharmaceuticals | Jun 16, 2025 | 1,250 |
| NCT05577468Helicobacter Pylori Infection · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Sep 30, 2023 | 561 |
| NCT05353010Healthy · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Jul 1, 2022 | 12 |
| NCT05010954Duodenal Ulcer · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Sep 28, 2022 | 400 |
| NCT05267743Erosive Reflux Disease · Korea, Republic of | 4 | Completed | HK inno.N | May 25, 2022 | 218 |
| NCT04840550Preventive Peptic Ulcer · South Korea | 3 | Completed | HK inno.N | Jul 1, 2025 | 392 |
| NCT04639804Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 26, 2020 | 60 |
| NCT04494269Hepatic Impairment · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Jun 2023 | 28 |
| NCT04309916Erosive Reflux Disease · Korea, Republic of | 4 | Completed | HK inno.N | Nov 30, 2021 | 46 |
| NCT04231136Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 29, 2020 | 19 |
| NCT04221321Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Mar 12, 2020 | 32 |
| NCT04171687Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Feb 7, 2020 | 36 |
| NCT04128917Helicobacter Pylori Infection · Korea, Republic of | 3 | Completed | HK inno.N | Dec 21, 2020 | 102 |
| NCT04066257Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Feb 22, 2019 | 32 |
| NCT04022096Healed Erosive Esophagitis · Korea, Republic of | 3 | Completed | HK inno.N | Jun 23, 2021 | 351 |
| NCT03863938Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Apr 26, 2019 | 12 |
| NCT03814642Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jul 22, 2019 | 25 |
| NCT03615677Erosive Esophagitis (EE) · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Oct 18, 2019 | 261 |
| NCT03591653Non-Erosive Reflux Disease · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Oct 30, 2019 | 291 |
| NCT03530228Pharmacodynamics · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Aug 2018 | 44 |
| NCT03498456Helicobacter Pylori Infection · Korea, Republic of | 3 | Completed | HK inno.N | Dec 31, 2019 | 284 |
| NCT03458650Healthy · China | 1 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Apr 23, 2018 | 38 |
| NCT03378284Pharmacodynamics · Korea, Republic of | 1 | Completed | HK inno.N | Dec 23, 2017 | 16 |
| NCT03317223Helicobacter Pylori Infection · Korea, Republic of | 3 | Completed | HK inno.N | Jan 21, 2019 | 350 |
| NCT03043521Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Aug 12, 2015 | 24 |
| NCT03009760Healthy | 1 | Completed | HK inno.N | Apr 2016 | 16 |
| NCT03011996Drug Interaction · Korea, Republic of | 1 | Completed | HK inno.N | Feb 2017 | 60 |
| NCT02995239Erosive Esophagitis · Korea, Republic of | 1 | Completed | HK inno.N | Apr 2015 | 12 |
| NCT03006874Erosive Esophagitis · Korea, Republic of | 3 | Completed | HK inno.N | Mar 24, 2017 | 302 |
| NCT02761512Stomach Ulcer · Korea, Republic of | 3 | Completed | HK inno.N | Jul 26, 2018 | 306 |
| NCT02556021Non-Erosive Reflux Disease · Korea, Republic of | 3 | Completed | HK inno.N | Nov 1, 2016 | 324 |
| NCT02456935Erosive Esophagitis · Korea, Republic of | 3 | Completed | HK inno.N | Jul 2016 | 280 |
| NCT02052336Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jan 2014 | 24 |
| NCT02028663Gastroesophageal Reflux · Korea, Republic of | 2 | Completed | HK inno.N | May 2014 | 206 |
| NCT01830309Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Feb 2013 | 24 |
| NCT01473173Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Aug 2012 | 59 |
How it is read
Names in the registry
- “Tegoprazan”, 10 entries
- “Tegoprazan 50 mg”, 5 entries
- “BLI5100”, 3 entries
- “Tegoprazan 50mg”, 3 entries
- “CJ-12420 50mg”, 3 entries
Conditions, from the studies’ own filings
- Esophagitis, 6 studies
- Non-Erosive Reflux Disease, 4 studies
- Gastroesophageal Reflux, 4 studies
- Peptic Ulcer, 1 study
- Duodenal Ulcer, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.